<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Christina Peter</style></author><author><style face="normal" font="default" size="100%">Halimat Yusuf Lukman</style></author><author><style face="normal" font="default" size="100%">Nosipho Wendy S’thebe</style></author><author><style face="normal" font="default" size="100%">Usman Abiola Sanni</style></author><author><style face="normal" font="default" size="100%">Saheed SABIU</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanistic Insights on the Neuro-Modulatory Potential of Cannabis sativa: A Network Pharmacology- and Molecular Dynamics Simulation-Based Approach</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cannabinoid receptors</style></keyword><keyword><style  face="normal" font="default" size="100%">Cannabis</style></keyword><keyword><style  face="normal" font="default" size="100%">Depression</style></keyword><keyword><style  face="normal" font="default" size="100%">Neurological diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Neurotransmitters</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2025</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">407-419</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Although, studies have reported the use of cannabis as a temporary antidepressant and implicated its chronic use in neurological diseases, the exact mechanisms through which these happen remain elusive. &lt;strong&gt;Objective:&lt;/strong&gt; This study aims to investigate the neuro-modulatory potential of cannabis as antidepressant and its role in neurological disorders &lt;strong&gt;Methodology: &lt;/strong&gt;Network pharmacology and molecular dynamics simulation were employed to unveil the mechanism of cannabis as a temporary antidepressant and potential agent implicated in neurological disorders.&lt;strong&gt; Results: &lt;/strong&gt;A total of 156 cannabis metabolites were retrieved from data mining. 22 genes were common in cannabis metabolites and central nervous system (&lt;em&gt;CNS&lt;/em&gt;) neurotransmitters’ genes. Glutamate receptor activity and neuroactive ligand receptor activity (&lt;em&gt;NALR&lt;/em&gt;) were the most enriched biological process and signalling pathway, respectively, with cannabinoid receptor 1 (&lt;em&gt;CNR1)&lt;/em&gt; and glutamate metabotropic receptor 2 (&lt;em&gt;GRM2&lt;/em&gt;) being the hub targets in the NALR pathway. A probe into the structural stability of top-ranked metabolites identified cholesterol- &lt;em&gt;CNR1&lt;/em&gt; (-73.88 kcal/mol) and campesterol-&lt;em&gt;CNR1&lt;/em&gt; (-65.96 kcal/mol) with lower free binding energy than reference antidepressant drug (anandamide) (-65.08 kcal/mol), whereas for &lt;em&gt;GRM2&lt;/em&gt;, the binding free energy of nerolidol (-43.57 kcal/mol) which was the least among the top ranked metabolites was higher compared to anandamide (-58.78 kcal/mol). &lt;strong&gt;Conclusion: &lt;/strong&gt;Data from this study shows that the profiled cannabis metabolites displayed modulatory effects on key neurotransmitters of the CNS and their receptors and formed stable binding interaction with genes implicated in brain functioning suggestive of the mechanistic effect of cannabis on brain activity during depression and chronic use.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">407</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Christina Peter&lt;sup&gt;1&lt;/sup&gt;, Halimat Yusuf Lukman&lt;sup&gt;1&lt;/sup&gt;, Nosipho Wendy S’thebe&lt;sup&gt;1&lt;/sup&gt;, Usman Abiola Sanni&lt;sup&gt;2,3&lt;/sup&gt;, Saheed Sabiu&lt;sup&gt;1*&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Biotechnology and Food Science, Faculty of Applied Sciences, Durban University of Technology, P. O. Box 1334, Durban 4000, SOUTH AFRICA&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Paediatrics, Federal Medical Centre, Birnin Kebbi, Nigeria, WEST AFRICA&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Partners in Health, Koidu, Kono, Sierra Leone, WEST AFRICA&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abdullahi Temitope Jamiu</style></author><author><style face="normal" font="default" size="100%">Christiana Eleojo Aruwa</style></author><author><style face="normal" font="default" size="100%">Ismail Abiodun Abdulakeem</style></author><author><style face="normal" font="default" size="100%">Abdulwakeel Ayokunnun Ajao</style></author><author><style face="normal" font="default" size="100%">Saheed SABIU</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phytotherapeutic Evidence Against Coronaviruses and Prospects for COVID-19</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antivirals</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronavirus</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug target</style></keyword><keyword><style  face="normal" font="default" size="100%">Natural products</style></keyword><keyword><style  face="normal" font="default" size="100%">Plant metabolites</style></keyword><keyword><style  face="normal" font="default" size="100%">Plants</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">September 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">1252-1267</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The emergence of the novel β-coronavirus (SARS-CoV-2) and subsequent outbreak of COVID-19, is a global health challenge with no known treatment to date and has culminated in significant morbidity and mortality. This article highlights current understanding on SARSCoV- 2 based on the available scientific evidence on human coronavirus (HCoV) infections, which could offer novel insights and therapeutic targets for SARS-CoV-2, the causative agent of COVID-19. Specifically, the paper presents available phytotherapeutic evidence against pathogenic HCoVs with a view to identifying potent plant-derived antiviral agents that could be developed to aid the fight against coronaviruses and the current COVID-19. Evidently, elucidation of CoV integral proteins such as the spike protein, angiotensin-converting enzyme 2, 3C-like cysteine protease and papain-like protease, as good targets for drug developments has lent credence to the use of medicinal plants or their metabolites as prophylaxis or treatment interventions in CoV infections and holds promising ground for SARS-CoV-2. While some promising phytocompounds are currently under clinical trials for COVID-19, increased research into plants and in-depth characterization of their metabolites could reveal more interesting results that would benefit humanity in its fight against emerging and re-emerging viral infections including the current COVID-19. Overall, given the current body of evidence on the potential development of phytotherapeutics for COVID-19, fears need to be allayed while clinical trials continue. Conclusively, the lockdown and other preventive measures which have been implemented in most parts of the world should be humanely exercised and supported to ensure compliance and safety of lives.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1252</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Abdullahi Temitope Jamiu&lt;sup&gt;2&lt;/sup&gt;, Christiana Eleojo Aruwa&lt;sup&gt;1&lt;/sup&gt;, Ismail Abiodun Abdulakeem&lt;sup&gt;3,&lt;/sup&gt; Abdulwakeel Ayokun-nun Ajao&lt;sup&gt;4&lt;/sup&gt; and Saheed Sabiu&lt;sup&gt;1,&lt;/sup&gt;*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Biotechnology and Food Technology, Durban University of Technology, P.O. Box 1334, Durban, 4000, SOUTH AFRICA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Microbial, Biochemical and Food Technology, University of the Free State, Bloemfontein 9300, SOUTH AFRICA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Biological Sciences, Al- Hikmah University, Ilorin, NIGERIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Botany and Plant Biotechnology, University of Johannesburg, P.O. Box 524, Auckland Park APK, 2006, SOUTH AFRICA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Emmanuel Oladipo AJANI</style></author><author><style face="normal" font="default" size="100%">Saheed SABIU</style></author><author><style face="normal" font="default" size="100%">Kuburat Temitope ODUFUWA</style></author><author><style face="normal" font="default" size="100%">Taiwo Bashir Ibrahim</style></author><author><style face="normal" font="default" size="100%">Bamidele Adewale Salau</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of Lens Aldose Reductase Inhibitory and Free Radical Scavenging Potential of Fractions of Lonchocarpus cyanescens: Potential for Cataract Remediation</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aldose reductase</style></keyword><keyword><style  face="normal" font="default" size="100%">Cataract</style></keyword><keyword><style  face="normal" font="default" size="100%">Free radical</style></keyword><keyword><style  face="normal" font="default" size="100%">Medicinal plant</style></keyword><keyword><style  face="normal" font="default" size="100%">Phytochemical constituents.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2016</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">62-69</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; Current research effort at discovering effective anticataract agent is focus on evaluating Aldose reductase inhibition (ARI) capacities of medicinal plants and plant extracts. The present study was aimed at investigating the &lt;em&gt;in vitro&lt;/em&gt; ARI activity of fractions of &lt;em&gt;Lonchocarpus cyanescens&lt;/em&gt; leaves on partially purified AR from goat lens. &lt;strong&gt;Methods:&lt;/strong&gt; Phytochemical constituents of the leaves were screened for using aqueous and methanolic extract while &lt;em&gt;in vitro&lt;/em&gt; free radical scavenging and ARI activities of the fractions were evaluated using partially purified aldose reductase. Kinetics of the enzyme in the presence of fractions of the leaves was then compared using Lineweaver-Burk plot. &lt;strong&gt;Results:&lt;/strong&gt; Phenol, flavonoid, tannins and phlobatannins were detected in both extracts. All the fractions inhibited AR significantly but this was strongest with aqueous (IC&lt;sub&gt;50&lt;/sub&gt;, 0.06 &amp;plusmn; 0.02 mM&lt;sup&gt;-1&lt;/sup&gt; and chloroform fractions (IC50, 0.09 &amp;plusmn; 0.01 mM&lt;sup&gt;-1&lt;/sup&gt;). Ethyl acetate, hexane and methanol fraction showed competitive inhibition whereas the aqueous and chloroform fractions showed mixed inhibition with a different V&lt;sub&gt;max&lt;/sub&gt; and K&lt;sub&gt;m &lt;/sub&gt;when compared with DL-glyceraldehyde. All the fractions also showed antioxidant capacities but this was also strongest with aqueous fraction. &lt;strong&gt;Conclusion:&lt;/strong&gt; The study confirms the ARI and antioxidant capacity of &lt;em&gt;Lonchocarpus cyanescens&lt;/em&gt; which may be attributed to its phenolic constituents and whose extraction is solvent dependent. The plant may therefore serve as a base for the development of anticataract agent.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">62</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Emmanuel Oladipo Ajani&lt;sup&gt;1*&lt;/sup&gt;, Saheed Sabiu&lt;sup&gt;1,2&lt;/sup&gt;, Kuburat Temitope Odufuwa&lt;sup&gt;3&lt;/sup&gt;, Taiwo Bashir Ibrahim&lt;sup&gt;1&lt;/sup&gt; and Bamidele Adewale Salau&lt;sup&gt;4&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Kwara State University, Malete, Department of Biosciences and Biotechnology, Phytomedicine and Drug Development Laboratory, P. M. B. 1530, Ilorin, Nigeria.&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;University of the Free State, Faculty of Natural and Agricultural Science South Africa.&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Biochemistry, OlabisiOnabanjoUnivesity, Remo Campus, Ikenne, Nigeria.&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Chemical sciences/Natural sciences, Redemer&amp;rsquo;s University, Ede, Osun State.&lt;/p&gt;
</style></auth-address></record></records></xml>